Anthos Therapeutics is developing abelacimab, a novel anticoagulant targeting Factor XI to reduce the risk of periprocedural bleeding in patients requiring anticoagulant therapy for cardiovascular and metabolic diseases. This approach addresses the significant undertreatment of patients with atrial fibrillation and cancer-associated thrombosis due to concerns over bleeding risks.
Funding
$250M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients requiring anticoagulant therapy for cardiovascular and metabolic diseases, such as those with atrial fibrillation and cancer-associated thrombosis, are undertreated due to the high risk of bleeding associated with current anticoagulants. This limitation in treatment options contributes to significant morbidity and mortality.
Solution
Anthos Therapeutics is developing abelacimab, a novel anticoagulant that selectively targets Factor XI (FXI). By inhibiting FXI, abelacimab aims to reduce the risk of periprocedural bleeding compared to traditional anticoagulants like warfarin and direct oral anticoagulants (DOACs). This hemostasis-sparing approach has the potential to expand the use of anticoagulation therapy to a broader range of patients who are currently undertreated due to bleeding concerns. Clinical data suggests that abelacimab may offer a paradigm shift in the prevention of stroke and other thrombotic conditions, with remarkably low levels of periprocedural bleeding observed in studies.
Target Audience
The primary target audience includes patients with cardiovascular and metabolic diseases, particularly those with atrial fibrillation and cancer-associated thrombosis, who require anticoagulant therapy but are at high risk of bleeding.
Features
- Selective inhibition of Factor XI (FXI) to disrupt the intrinsic coagulation pathway
- Designed to provide effective anticoagulation while minimizing bleeding risk
- Investigational agent currently in clinical development; not yet approved for any indication
- Potential to address the undertreatment of patients with atrial fibrillation and cancer-associated thrombosis